Vesicular Stomatitis Virus-Based Vaccines for Prophylaxis and Treatment of Filovirus Infections.

Authors:
Address: Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, USA.
Journal:

Publication:
Free Text: Vesicular Stomatitis Virus-Based Vaccines for Prophylaxis and Treatment of Filovirus Infections.

abstract

Ebola and Marburg Viruses are emerging/re-emerging zoonotic pathogens that cause severe viral hemorrhagic fever with case-fatality rates up to 90% in humans. Over the last three decades numerous outbreaks, of increasing frequency, have been documented in endemic regions. Furthermore, as a result of increased international travel Filovirus Infections have been imported into South Africa, Europe and North America. Both viruses possess the potential of being used as bioterrorism agents and are classified as category A pathogens. Currently there is neither a licensed vaccine nor effective Treatment available, despite substantial efforts being d́edicated to understanding filovirus well as vaccine and drug development. One of the most promising vaccine platforms is Based on replication competent recombinant Vesicular Stomatitis viruses (rVSV) that express a filovirus glycoprotein as the surface antigen. These rVSVs have been extensively studied in rodent and nonhuman primate models of filovirus disease and, in general, have been shown to be 100% protective in pre-exposure Prophylaxis. In addition, rVSVs have demonstrated potential for post-exposure treatment, and thus would be particularly useful in the event of intentional release as well as accidental exposures in outbreak and laboratory settings.

Related Articles
Review Recombinant vesicular stomatitis virus-based vaccines against Ebola and Marburg virus infections.
J Infect Dis. 2011
Review Recombinant vesicular stomatitis virus-based vaccines against Ebola and Marburg virus infections.
Geisbert TW, Feldmann H. J Infect Dis. 2011 Nov; 204 Suppl 3:S1075-81.
Review Prospects for immunisation against Marburg and Ebola viruses.
Rev Med Virol. 2010
Review Prospects for immunisation against Marburg and Ebola viruses.
Geisbert TW, Bausch DG, Feldmann H. Rev Med Virol. 2010 Nov; 20(6):344-57.
Recombinant vesicular stomatitis virus vaccine vectors expressing filovirus glycoproteins lack neurovirulence in nonhuman primates.
PLoS Negl Trop Dis. 2012
Recombinant vesicular stomatitis virus vaccine vectors expressing filovirus glycoproteins lack neurovirulence in nonhuman primates.
Mire CE, Miller AD, Carville A, Westmoreland SV, Geisbert JB, Mansfield KG, Feldmann H, Hensley LE, Geisbert TW. PLoS Negl Trop Dis. 2012 Mar; 6(3):e1567. Epub 2012 Mar 20.
Vaccine to confer to nonhuman primates complete protection against multistrain Ebola and Marburg virus infections.
Clin Vaccine Immunol. 2008
Vaccine to confer to nonhuman primates complete protection against multistrain Ebola and Marburg virus infections.
Swenson DL, Wang D, Luo M, Warfield KL, Woraratanadharm J, Holman DH, Dong JY, Pratt WD. Clin Vaccine Immunol. 2008 Mar; 15(3):460-7. Epub 2008 Jan 23.
Effective post-exposure treatment of Ebola infection.
PLoS Pathog. 2007
Effective post-exposure treatment of Ebola infection.
Feldmann H, Jones SM, Daddario-DiCaprio KM, Geisbert JB, Ströher U, Grolla A, Bray M, Fritz EA, Fernando L, Feldmann F, et al. PLoS Pathog. 2007 Jan; 3(1):e2.

To top • Home

TraveldoctorOnline 2001 • Disclaimer • webmaster

The contents within traveldoctoronline are presented only for informational purposes and cannot substitute for professional health care or any other medical treatment.All users of this website with health problems should be oblige always to consult their medical doctor before starting any treatment.